AB-248 is under clinical development by Asher Biotherapeutics and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AB-248’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-248 is under development for the treatment of locally advanced or metastatic solid tumors, including melanoma, renal cell carcinoma (RCC), non-small cell lung carcinoma (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). The drug candidate comprises mutant interleukin-2 polypeptides fused with antibody fragment. The drug candidate acts by targeting Interleukin 2 Receptor (IL2R). It is developed based on cis-targeting discovery platform. It is administered through intravenous route.
Asher Biotherapeutics overview
Asher Biotherapeutics., is a health care services provider that develops immunotherapy drugs designed to treat cancer. The company is headquartered in United States.
For a complete picture of AB-248’s drug-specific PTSR and LoA scores, buy the report here.